Minervax ApS
Edit

Minervax ApS

http://minervax.com/
Last activity: 18.11.2023
Tags:BioTechCauseDeliveryDevelopmentHealthTechLifeMedTechPublicResearch
MinervaX is pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS). The vaccine is based on adjuvanted proteins antigens covering close to 100% of clinical GBS isolates. Group B Streptococcal (GBS) is the leading cause of life-threatening infections in newborns. Colonization of pregnant women with GBS may lead to adverse pregnancy outcomes such as late abortions, stillbirths, and preterm delivery. Colonization may also lead to life-threatening infections in newborns for the first 3 months of life, causing pneumonia, septicemia and meningitis, which may lead to death or life-long disability. Annually, GBS is responsible for some 320,000 cases of neonatal invasive disease, 60,000 stillbirths, 3,500,000 preterm deliveries, and 10,000 babies suffering from long-term neurological damage world-wide.
Mentions
12
Location: Denmark, Capital Region of Denmark, Copenhagen
Employees: 1-10
Total raised: $196.506521M

Investors 4

Funding Rounds 4

DateSeriesAmountInvestors
12.10.2023-$57.262168...-
15.12.2022-$76.434581...Trill Impa...
15.12.2020Series B$57.809954...Industrifo...
22.01.2019-$4.999818M-

Mentions in press and media 12

DateTitleDescriptionSource
12.10.2023Denmark-based MinervaX announces closure of Upsized financin...Copenhagen, Denmark-based biotechnology company developing a novel, prophylactic vaccine against Gro...vcbay.news...
11.10.2023Denmark’s MinervaX raises €54M to prevent life-threatening i...Read this article in: Denmark-based biotechnology company MinervaX ApS announced the completion of ...siliconcan...
11.10.2023MinervaX Raises EUR 54M in Upsized Financing to Advance the ...-orbimed.co...
11.10.2023MinervaX Raises EUR 54M in Upsized FinancingMinervaX, a Copenhagen, Denmark-based biotechnology company, raised EUR54M in upsized financing. Th...finsmes.co...
15.12.2022MinervaX Raises €72M FinancingMinervaX, a Copenhagen, a Denmark-based biotechnology company, raised €72M in funding. The €22M equ...finsmes.co...
15.12.2022Trill Impact Ventures co-leads the EUR 22M financing round i...Trill Impact Ventures co-leads the EUR 22M financing round in MinervaX Thu, Dec 15, 2022 08:00 CET ...news.cisio...
16.12.2020MinervaX Raises Upsized Eur 47.4 Million (USD 57M) Series B ...On the back of highly promising Phase Ib data, MinervaX has raised financing from leading investors ...aithority....
15.12.2020MinervaX raises upsized EUR 47.4M (USD 57M) Series B to adva...MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B S...wellington...
15.12.2020MinervaX raises $57M for Group B streptococcus vaccine race ...Despite decades of research, there is still no effective vaccine against Group B streptococcus (GBS)...fiercebiot...
15.12.2020MinervaX raises $57M for Group B streptococcus vaccine race ...Despite decades of research, there is still no effective vaccine against Group B streptococcus (GBS)...fiercebiot...
Show more